What began decades ago as a niche scientific field focused on genetic engineering and biological research has grown into a market worth well over $1.7 trillion globally.
Today, biotechnology companies are behind many of the most important medical breakthroughs, including gene therapies, mRNA vaccines, monoclonal antibodies, cell therapies, and precision medicines that are transforming the way diseases are diagnosed and treated.
Global pharmaceutical and biotechnology R&D spending has nearly doubled since 2016, reaching about $300 billion in 2025. Meanwhile, biotech licensing deals involving companies in Greater China surged to $137.7 billion in 2025, almost 10 times the 2021 level. [1][2]
Below are the largest biotech companies in the world, with vast manufacturing networks capable of producing billions of doses of medicines and vaccines each year. These industry leaders stand out not only for their revenue and market value but also for their scientific breakthroughs, global presence, research expertise, and role in shaping the future of healthcare.
Did you know?
The global biotech market is projected to surpass $6.3 trillion by 2035, growing at a CAGR of 13.61%. This growth is being driven by rising demand for biologics, gene therapies, and precision medicine. [3]
Table of Contents
14. Illumina: Backbone of modern genomics
Founded: 1998Country: United States
Revenue: $4.39 billion+
Competitive Edge: Dominance in DNA sequencing
Illumina is one of the most important biotech companies, not because it develops drugs, but because it provides the technology that enables much of modern genetic medicine.
The cost of sequencing a human genome has fallen from approximately $100 million in the early 2000s to well under $500 today, and Illumina has been one of the primary drivers behind this dramatic cost reduction.
Illumina’s flagship platforms, including NovaSeq X, NextSeq, and MiSeq, are designed to support applications ranging from academic research to large-scale population genome projects.
More than 25,000 Illumina sequencing systems have been installed globally, and the company’s technologies have contributed to sequencing millions of human genomes.
13. Alnylam Pharmaceuticals: Gene-silencing pioneer
Country: United States
Revenue: $4.29 billion+
Competitive Edge: Leadership in RNA interference technology
Alnylam was founded on a breakthrough scientific idea: the ability to selectively “silence” disease-causing genes before harmful proteins are produced. They have proved that RNA interference (RNAi) therapeutics can become a powerful new category of medicine. [4]
Their commercial portfolio includes Amvuttra, Onpattro, Givlaari, and Oxlumo, all of which are based on RNAi technology and target rare genetic disorders.
With annual R&D spending of over $1.32 billion, the company is advancing new delivery systems that could make its therapies more effective, reach more tissues, and require fewer doses.
T Financially, Alnylam Pharmaceuticals has entered a new phase of growth. In FY 2026, it generated $4.29 billion in revenue, a 82.57% increase year-over-year and a 65.19% increase from 2024.
12. Sarepta Therapeutics: Fighting against genetic muscle diseases
Founded: 1980Country: United States
Revenue: $2.2 billion+
Competitive Edge: First-mover advantage in DMD gene therapy
Sarepta Therapeutics focuses almost entirely on precision genetic medicine for rare neuromuscular diseases. It has spent decades developing therapies for devastating inherited disorders, particularly Duchenne muscular dystrophy (DMD), one of the most severe genetic diseases affecting children.
Today, Sarepta’s portfolio includes approved exon-skipping therapies such as Exondys 51, Vyondys 53, and Amondys 45, as well as ELEVIDYS, the first FDA-approved gene therapy for Duchenne muscular dystrophy. These products target the genetic causes of disease rather than simply treating symptoms
In 2025, the company generated $2.2 billion in total revenue, while total net product revenue reached $1.86 billion. ELEVIDYS alone generated $899 million in product revenue during that year.
11. Genmab: Europe’s antibody innovation champion
Founded: 1999Country: Denmark
Revenue: $3.9 billion+
Competitive Edge: World-class antibody engineering platforms
Genmab has concentrated much of its expertise on oncology and antibody engineering, becoming one of the most respected names in cancer biotechnology.
Its proprietary technology platforms (such as DuoBody, HexaBody, and Epkinly-related antibody technologies) enable scientists to design next-generation antibodies with enhanced efficacy against cancer cells.
Genmab’s success has been driven largely by Darzalex (daratumumab), a multiple myeloma treatment developed with Johnson & Johnson. Darzalex has become one of the world’s best-selling cancer medicines, generating global sales exceeding $14 billion annually.
In FY 2026, the company reported $3.9 billion in revenue, supported by royalty income, product sales, and collaboration agreements.
Furthermore, products like Epkinly (epcoritamab), Tivdak, and future pipeline candidates are expected to increase Genmab’s direct commercial revenue while reducing dependence on Darzalex royalties over time. [5]
10. BioMarin Pharmaceutical: Solving medicine’s rarest challenges
Founded: 1997Country: United States
Revenue: $3.2 billion+
Competitive Edge: Strong orphan drug portfolio
BioMarin develops therapies for patients with serious genetic disorders. It focuses on developing therapies that address the root causes of genetic disorders rather than merely managing symptoms.
Unlike many biotech companies that target large patient populations, BioMarin concentrates on diseases affecting relatively small numbers of patients worldwide. This strategy has allowed the company to build deep scientific expertise in genetics, enzyme replacement therapies, and gene therapy.
Today, BioMarin markets treatments for conditions including achondroplasia, phenylketonuria (PKU), hemophilia A, mucopolysaccharidosis, and other rare inherited disorders.
One of its most transformative achievements has been Voxzogo, a treatment for achondroplasia, the most common form of dwarfism.
The company is also a major innovator in gene therapy. Through Roctavian, BioMarin developed one of the first approved gene therapies for severe hemophilia A. [6]
9. Moderna: Future of programmable medicine
Country: United States
Revenue: $2.2 billion+
Competitive Edge: Proprietary mRNA technology
Moderna is one of the most influential biotech companies of the 21st century. It is responsible for bringing messenger RNA (mRNA) medicine into mainstream healthcare.
The company achieved global prominence through Spikevax (its COVID-19 vaccine), which became one of the fastest-developed and most widely distributed vaccines in history. During the pandemic peak, Moderna generated more than $18 billion in annual revenue, demonstrating the enormous commercial potential of mRNA technology.
Moderna is now transitioning from a pandemic-era vaccine company into a diversified biotechnology platform. Although revenue declined to $2 billion in 2025 as COVID vaccine demand normalized, the company continues investing heavily in future growth opportunities. [7]
In FY 2026, it spent approximately $2.9 billion in R&D and believes up to 10 of its products could gain regulatory approval in the years ahead.
8. Biogen: Pioneer in neurological innovation
Founded: 1978Country: United States
Revenue: $9.93 billion+
Competitive Edge: Therapies for AD and MS
Biogen was co-founded by five world-renowned scientists, including Nobel Prize winners, making it one of the most scientifically prestigious biotechnology startups ever created.
The company focuses on developing treatments for neurological disorders, rare diseases, and immune-related conditions. Its research targets some of medicine’s toughest challenges, including Alzheimer’s Disease (AD), Multiple Sclerosis (MS), spinal muscular atrophy, and rare genetic disorders.
Through its partnership with Eisai, Biogen co-developed Leqembi, one of the first Alzheimer’s treatments shown to slow disease progression.
Combined with growing rare-disease products such as Skyclarys and neuroscience therapies like Zurzuvae, Biogen is attempting to redefine itself as a next-generation neurological disease leader.
The company ended 2025 with nearly $4.2 billion in cash, cash equivalents, and marketable securities. This provides enough flexibility for research investments, acquisitions, and strategic partnerships. [8]
7. Vertex Pharmaceuticals: Precision medicine at its best
Country: United States
Revenue: $12 billion+
Competitive Edge: Near-monopoly in Cystic Fibrosis
Vertex is widely regarded as a gold standard for disease-focused innovation. It spent decades pursuing a highly targeted strategy: developing transformative medicines for serious diseases with significant unmet medical needs.
Unlike many biotech firms that spread resources across numerous therapeutic areas, Vertex built its reputation by dominating a single disease category — Cystic Fibrosis (CF) — before expanding into gene editing, pain management, kidney disease, and type 1 diabetes.
Today, Vertex leads the Cystic Fibrosis market with medicines such as Trikafta/Kaftrio and Alyftrek, which address the root genetic cause of the disease rather than only relieving symptoms.
Vertex is also focusing on diversifying its business. They have launched CASGEVY (the world’s first approved CRISPR gene-editing therapy) and JOURNAVX (the first new class of non-opioid acute pain medicine approved in more than 20 years).
Financially, the company finished 2025 with approximately $12.3 billion in cash and marketable securities, giving it one of the strongest balance sheets in the biotech sector.
6. CSL: Leading plasma-derived medicines
Founded: 1916Country: Australia
Revenue: $15.6 billion+
Competitive Edge: Massive plasma collection network
CSL Limited specializes in plasma-derived therapies, vaccines, and treatments for rare and serious diseases. Its products help patients with immune disorders, bleeding conditions, respiratory illnesses, neurological diseases, and infectious diseases.
Plasma therapies, in particular, are among the most complex biologic products to manufacture because they require collecting and processing human plasma from hundreds of thousands of donors.
CSL operates more than 330 plasma collection centers globally, making it one of the world’s largest plasma collectors. This infrastructure creates a significant barrier to entry for rivals and provides a durable competitive advantage.
Financially, CSL ranks among the largest biotechnology companies outside the United States. Its three major businesses provide diversification: CSL Behring (plasma therapies), CSL Seqirus (vaccines), and CSL Vifor (kidney disease and iron deficiency).
CSL Seqirus, the influenza vaccine division, supplies vaccines worldwide and has become one of the few companies capable of producing traditional and cell-based flu vaccines at a global scale.
5. Regeneron Pharmaceuticals: Genetics meets drug discovery
Founded: 1988Country: United States
Revenue: $14.92 billion+
Competitive Edge: Partnerships with major healthcare firms
Regeneron has built its reputation on scientific innovation and advanced biologics. Many of its key therapies were developed using its proprietary technologies, such as the VelocImmune platform.
The company spends over $6 billion annually on R&D and currently has approximately 45 clinical-stage product candidates under development. The pipeline spans cancer, immunology, ophthalmology, obesity, cardiovascular disease, rare disorders, and genetic medicine. [9]
Regeneron’s biggest commercial success is Dupixent, a breakthrough immunology medicine co-developed with Sanofi. In 2025, Dupixent’s sales reached $17.8 billion, making it one of the best-selling medicines globally.
Regeneron is also a major player in ophthalmology, with EYLEA and EYLEA HD ranking among the world’s leading treatments for retinal diseases.
4. AbbVie: Driving next era of immunology
Country: United States
Revenue: $62.8 billion+
Competitive Edge: Diversified business model
AbbVie is one of the world’s largest biotech companies and a remarkable example of corporate transformation. Formed as a spin-off from Abbott Laboratories, AbbVie inherited one of the most successful drugs in pharmaceutical history — Humira.
Over the last decade, AbbVie has accomplished what many analysts considered nearly impossible. It replaced a large portion of Humira’s lost revenue with newer therapies before the patent cliff caused a major decline in the company’s overall financial performance.
Today, AbbVie’s greatest strength is immunology. It has developed next-gen medicines such as Skyrizi and Rinvoq, which have become two of the fastest-growing drugs in the pharmaceutical industry.
In 2020, AbbVie acquired Allergan for $63 billion. This was a milestone as it transformed AbbVie into a diversified healthcare company by adding aesthetics, neuroscience, and eye-care businesses. The deal also brought Botox, one of the most famous healthcare brands globally, under AbbVie’s ownership. [10]
The company continues to invest heavily in neuroscience and is expanding its presence in migraine treatment, psychiatry, Parkinson’s disease, and neurodegenerative disorders.
3. Gilead Sciences: Leading antiviral medicine
Country: United States
Revenue: $29.7 billion+
Competitive Edge: Dominance in HIV treatment
Gilead Sciences is best known for revolutionizing the treatment of HIV/AIDS, transforming what was once a fatal disease into a manageable chronic condition for millions of patients.
Today, it operates across virology, oncology, inflammation, and cell therapy, with products available in 35+ countries and patients treated worldwide.
Its flagship HIV portfolio, including Biktarvy, Descovy, Genvoya, and Sunlenca, continues to dominate the global HIV market.
Gilead maintains one of the biotech industry’s strongest cash-flow profiles. In FY 2026, it invested roughly $5.7 billion in R&D to support hundreds of clinical programs across HIV, hepatitis, oncology, inflammation, and cell therapy. [11]
2. Amgen: Original biotech giant
Country: United States
Revenue: $36.75 billion+
Competitive Edge: Human genetics-driven drug discovery
Amgen is among the world’s largest independent biotechnology companies, developing medicines for cardiovascular disease, cancer, osteoporosis, inflammation, rare diseases, and obesity.
The company’s success comes from its ability to repeatedly identify major disease markets and develop blockbuster biologic therapies. It pioneered treatments such as Epogen, Neupogen, and Enbrel, which helped establish biotechnology as a viable pharmaceutical business model.
Today, Amgen’s growth portfolio includes products like Repatha, Prolia, Evenity, Tezspire, Otezla, Tepezza, and Blincyto, many of which are leaders in their respective therapeutic categories.
The company is now entering what may become its next major growth era: obesity treatment. Its experimental drug MariTide has emerged as one of the most closely watched obesity therapies in development.
In fact, they have initiated additional obesity research programs, including AMG 513, a next-generation obesity therapy with a novel mechanism of action. [12]
1. Roche: Combining biotech and diagnostics at scale
Country: Switzerland
Revenue: $78 billion+
Competitive Edge: Unique pharmaceuticals + Diagnostics combination
What makes Roche unique is its ability to combine biopharmaceuticals, diagnostics, genomics, digital health, and personalized medicine under a single corporate structure.
Many of its best-selling products (including Ocrevus, Hemlibra, Vabysmo, Tecentriq, and Phesgo) are advanced biologic medicines. These therapies address some of the world’s most challenging diseases, such as multiple sclerosis, hemophilia, retinal disorders, and cancer.
In 2025, Roche generated nearly $78 billion in revenue, with pharmaceuticals contributing 77.5% and diagnostics contributing 22.5%. The core operating profit stood at $27.6 billion.
That same year, the company invested approximately $15 billion in core R&D, one of the largest research budgets in the global healthcare industry. It advanced 10 new medicines into late-stage testing and reported positive results from 12 late-stage clinical readouts.
Plus, they signed a $5.3 billion deal with Zealand Pharma to co-develop the obesity drug candidate petrelintide. The therapy is considered a potential next-generation competitor to obesity treatments from Novo Nordisk and Eli Lilly. [13]
Read More
Sources Cited and Additional References- Pharmaceutical research and development (R&D), Statista
- Innovent Biologics and Pfizer strike a deal amid China biotech boom, Reuters
- Biotech market size and trend analysis, Precedence Research
- Pioneering RNA interference (RNAi) therapeutics, Alnylam
- DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push, Yahoo Finance
- First gene therapy for adults with severe Hemophilia A, BioMarin’s ROCTAVIAN
- Moderna reports Q4 and FY 2025 financial results, Nasdaq
- Biogen reports strong Q4 and FY 2025 financial results, Biogen
- Full year 2025 revenues increased 1% to $14.3 billion, Regeneron
- AbbVie closed its $63-billion acquisition of Allergan, AbbVie
- Gilead Sciences R&D expenses throughout the years, Macrotrends
- Amgen is ‘aggressively expanding’ in obesity treatment, Investors
- Roche and Zealand Pharma’s $5.3 billion obesity drug gambit, CNBC
